Author(s):
Mikhail Kasatkin, Lyudmila Smirnova, Dmitrii Babaskin
Email(s):
mikh_kasatkin@rambler.ru
DOI:
10.52711/0974-360X.2021.01050 
Address:
Mikhail Kasatkin1*, Lyudmila Smirnova2, Dmitrii Babaskin3
1Department of Sports Medicine and Medical Rehabilitation, I.M. Sechenov First Moscow State Medical University (Sechenov University), Bolshaya Pirogovskaya str., 2, Moscow, 119435, Russian Federation.
2Department of Dermatology and Venereology, I.M. Sechenov First Moscow State Medical University (Sechenov University), Bolshaya Pirogovskaya str., 2, Moscow, 119435, Russian Federation.
3Department of Pharmacy, I.M. Sechenov First Moscow State Medical University (Sechenov University), Trubetskaya Str., 8-2, Moscow, 119991, Russian Federation.
*Corresponding Author
Published In:
Volume - 14,
Issue - 11,
Year - 2021
ABSTRACT:
The human microbiome is an integral part of the body, playing a crucial role in metabolism, energy homeostasis, the regulation of the immune system, and others. The study aims to examine the effect of probiotic ointment on the qualitative composition of the lesional skin microbiome in patients with atopic dermatitis. The study population consisted of 110 patients aged 20 to 45 years with mild atopic dermatitis (AD). The patients were divided into two groups. One group received four different medications: levocetirizine dihydrochloride, enterosgel, topical Tizol gel, and topical 1% hydrocortisone ointment. The other group received a similar treatment with four different medications: levocetirizine dihydrochloride, enterosgel, topical Tizol gel, and topical probiotic ointment. The treatment period was one month. After treatment, the frequency and intensity of the main AD symptoms significantly decreased. A load of S. aureus fell in the probiotic-treated group from 73.4% to 29.1% (p<.05). In the standard-treated group, the S. aureus load decreased from 78.2% to 43.6% (p<.05). The study found that the standard treatment without probiotics helped to decrease S. aureus colonisation in AD patients by 2.00 times (p<.05), whereas using the probiotic ointment reduced S. aureus colonisation by 3 times (p<.05).
Cite this article:
Mikhail Kasatkin, Lyudmila Smirnova, Dmitrii Babaskin. Therapeutic effects of Probiotic Ointment for Atopic Dermatitis. Research Journal of Pharmacy and Technology. 2021; 14(11):6041-8. doi: 10.52711/0974-360X.2021.01050
Cite(Electronic):
Mikhail Kasatkin, Lyudmila Smirnova, Dmitrii Babaskin. Therapeutic effects of Probiotic Ointment for Atopic Dermatitis. Research Journal of Pharmacy and Technology. 2021; 14(11):6041-8. doi: 10.52711/0974-360X.2021.01050 Available on: https://rjptonline.org/AbstractView.aspx?PID=2021-14-11-75
REFERENCES:
1. Integrative HMP (iHMP). Research network consortium. The integrative human microbiome project. Nature. 2019; 569:641-648. doi:10.1038/s41586-019-1238-8
2. Garud NR, Pollard KS. Population genetics in the human microbiome. Trends in Genetics. 2020; 36:53-67. doi.org/10.1016/j.tig.2019.10.010
3. West CE, Jenmalm MC, Prescott SL. The gut microbiota and its role in the development of allergic disease: a wider perspective. Clinical and Experimental Allergy. 2015; 45:43-53. doi.org/10.1111/cea.12332
4. Kharitonova LA, Grigoriev KI, Borzakova SN. Human microbiota: how a new scientific paradigm changes medical practice. Experimental and Clinical Gastroenterology. 2019; 161:55-63. doi.org/10.31146/1682-8658-ecg-161-1-55-63
5. Cong X, Henderson WA, Graf J, McGrath JM. Early life experience and gut microbiome: the brain-gut-microbiota signaling system. Advances in Neonatal Care. 2015; 15:314-323. doi.org/10.1097/ANC.0000000000000191
6. van der Meulen TA, Harmsen H, Bootsma H, Spijkervet FK, Kroese FG, Vissink A. The microbiome-systemic diseases connection. Oral Diseases. 2016; 22:719-734. doi.org/10.1111/odi.12472
7. Rejepov DT, Vodyashkin AA, Sergorodceva AV, Stanishevskiy YM. Biomedical Applications of Silver Nanoparticles (Review). Drug Development & Registration. 2021; 10(3):176-187. doi.org/10.33380/2305-2066-2021-10-3-176-187
8. Cryan JF, O'Riordan KJ, Cowan CS, Sandhu KV, Bastiaanssen TF, Boehme M, et al. The microbiota-gut-brain axis. Physiological Reviews. 2019; 99:1877-2013. doi.org/10.1152/physrev.00018.2018
9. Hayley S, Audet MC, Anisman H. Inflammation and the microbiome: implications for depressive disorders. Current Opinion in Pharmacology. 2016; 29:42-46. doi.org/10.1016/j.coph.2016.06.001
10. Benson AK. The gut microbiome—an emerging complex trait. Nature Genetics. 2016; 48:1301-1302. doi.org/10.1038/ng.3707
11. Cianci R, Pagliari D, Piccirillo CA, Fritz JH, Gambassi G. The microbiota and immune system crosstalk in health and disease. Mediators of Inflammation. 2018; 1: 2912539. doi.org/10.1155/2018/2912539
12. Kramer CD, Genco CA. Microbiota, immune subversion, and chronic inflammation. Frontiers in Immunology. 2017; 8:255-265. doi.org/10.3389/fimmu.2017.00255
13. Koleva PT, Bridgman SL, Kozyrskyj AL. The infant gut microbiome: evidence for obesity risk and dietary intervention. Nutrients. 2015; 7:2237-2260. doi.org/10.3390/nu7042237
14. Reynolds LA, Finlay BB, Maizels RM. Cohabitation in the intestine: interactions among helminth parasites, bacterial microbiota, and host immunity. The Journal of Immunology. 2015; 195:4059-4066. doi.org/10.4049/jimmunol.1501432
15. Iliev D, Leonardi I. Fungal dysbiosis: immunity and interactions at mucosal barriers. Nature Reviews Immunology. 2017; 17:635-646. doi.org/10.1038/nri.2017.55
16. Plaza-Diaz J, Ruiz-Ojeda FJ, Gil-Campos M, Gil A. Mechanisms of action of probiotics. Advances in Nutrition. 2019; 10:49-66. doi.org/10.1093/advances/nmy063
17. Bortnikova VV, Karabaeva VV, Krepkova LV, Mizina PG, Babenko AN, Mikheeva NS, et al. A retrospective analysis of the clinical studies of a drug flakozid in the treatment of diseases of the hepatobiliary system. Drug Development & Registration. 2021; 10(3):100-104. doi.org/10.33380/2305-2066-2021-10-3-100-104
18. Markowiak P, Śliżewska K. Effects of probiotics, prebiotics, and synbiotics on human health. Nutrients. 2017; 9:1021-1251. doi.org/10.3390/nu9091021
19. Reid G, Gadir AA, Dhir R. Probiotics: reiterating what they are and what they are not. Frontiers in Immunology. 2019; 10:424-430. doi.org/10.3389/fmicb.2019.00424
20. Sanders ME, Merenstein D, Merrifield CA, Hutkins R. Probiotics for human use. Nutrition Bulletin. 2018; 43:212-225. doi.org/10.1111/nbu.12334
21. FDA. Dietary supplements: new dietary ingredient notifications and related issues: guidance for industry, https://www.fda.gov/regulatory-information/search-fda-guidance-documents/draft-guidance-industry-new-dietary-ingredient-notifications-and-related-issues.
22. Lowe JR, Briggs AM, Whittle S, Stephenson MD. A systematic review of the effects of probiotic administration in inflammatory arthritis. Complementary Therapies in Clinical Practice. 2020; 40: 101207. doi.org/10.1016/j.ctcp.2020.101207
23. Mohammed AT, Khattab M, Ahmed AM, Turk T, Sakr N, Khalil AM, et al., The therapeutic effect of probiotics on rheumatoid arthritis: a systematic review and meta-analysis of randomised control trials. Clinical Rheumatology. 2017; 36: 2697–2707. doi.org/10.1007/s10067-017-3814-3
24. Tang Y, Huang J, Zhang WY, Qin S, Yang YX, Ren H, et al. Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. Therapeutic Advances in Gastroenterology. 2019; 12:1-23. doi.org/10.1177% 2F1756284819878046
25. Zhang Q, Gao F, Yang X, Hu Y, Liu Y, Hou Y, et al. Protective effect of probiotics against esophagogastric variceal rebleeding in patients with liver cirrhosis after endoscopic therapy. Medical Science Monitor: International Medical Journal of Experimental and Clinical Research. 2020. 26: e924040. doi.org/10.12659/ MSM.924040
26. Disamantiaji AP, Izza EF, Soelaeman MF, Sembiring T, Louisa M. Probiotics in the management of atopic dermatitis for children: a case-based review. Dermatology Research and Practice. 2020; 2020:4587459. doi.org/10.1155/2020/4587459
27. Jiang W, Ni B, Liu Z, Liu X, Xie W, Wu IX, Li X. The role of probiotics in the prevention and treatment of atopic dermatitis in children: an updated systematic review and meta-analysis of randomised controlled trials. Pediatric Drugs. 2020; 22:535-549. doi.org/10.1007/s40272-020-00410-6
28. Yu Y, Dunaway S, Champer J, Kim J, Alikhan A. Changing our microbiome: probiotics in dermatology. British Journal of Dermatology. 2019; 182:39-46. doi.org/10.1111/bjd.18088
29. Sivamaruthi BS, Kesika P, Chaiyasut C. A mini-review of human studies on cholesterol-lowering properties of probiotics. Scientia Pharmaceutica. 2019; 87:26. doi.org/10.3390/ scipharm87040026
30. Skonieczna-Żydecka K, Kaźmierczak-Siedlecka K, Kaczmarczyk M, Śliwa-Dominiak J, Maciejewska D, Janda K, et al. The effect of probiotics and synbiotics on risk factors associated with cardiometabolic diseases in healthy people—a systematic review and meta-analysis with meta-regression of randomised controlled trials. Journal of Clinical Medicine. 2020; 9:1788-1823. doi.org/10.3390/jcm9061788
31. Selezneva AI, Smirnov VA, Goryachkin VV, Chadova NN, Polyakov SV, Shestakov VN, et al. The integrated model of quality management system of laboratory studies of medicines (review). Drug Development & Registration. 2021; 10(3):148-165. doi.org/10.33380/2305-2066-2021-10-3-148-165
32. Suaini H, Tan CP, Loo EX, Tham EH. Global differences in atopic dermatitis. Pediatric Allergy and Immunology. 2020; 32:23-33. doi.org/10.1111/pai.13335
33. Yong MYA, Tay YK. Atopic dermatitis. Dermatologic Clinics. 2017; 35: 395-402. doi.org/10.1016/j.det.2017.02.012
34. Adamson AS. The economics burden of atopic dermatitis. In Management of Atopic Dermatitis 2017; 79–92. Springer, Cham. doi.org/10.1007/978-3-319-64804-0_8
35. Wollenberg A, Barbarot S, Bieber T, Christen‐Zaech S, Deleuran M, Fink‐Wagner A, et al. Consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. The Journal of the European Academy of Dermatology and Venereology. 2018; 32:850-878. doi.org/10.1111/jdv.14888
36. Wollenberg A, Szepietowski J, Taieb A, Ring J. Corrigendum: consensus‐based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part I. The Journal of the European Academy of Dermatology and Venereology. 2019; 33: 1436. doi.org/10.1111/jdv.14891
37. Pokatilov B. Colonisation and adhesion by microbes of the skin of patients in a surgical hospital in an ecologically unfavorable environment. Dissertation for the degree of candidate of sciences abstract, Volgograd 1993.
38. Murray PR, Rosenthal KS, Pfaller MA. Medical microbiology. Elsevier/Saunders, Philadelphia, USA 2013.
39. Menshikov VV. Clinical and laboratory research methods. Labora, Moscow 2009.
40. Gerbens LAA, Chalmers JR, Rogers NK, Nankervis H, Spuls PI, Harmonising Outcome Measures for Eczema (HOME) initiative. Reporting of symptoms in randomised controlled trials of atopic eczema treatments: a systematic review. British Journal of Dermatology. 2016; 175:678-686. doi.org/10.1111/bjd.14588
41. Vakharia PP, Chopra R, Sacotte R, Patel KR, Singam V, Patel N, et al. Burden of skin pain in atopic dermatitis. Annals of Allergy, Asthma and Immunology. 2017; 119:548-552. doi.org/10.1016/j.anai.2017.09.076
42. Brunner PM, Leung DYM, Guttman-Yassky E. Immunologic, microbial, and epithelial interactions in atopic dermatitis. Annals of Allergy, Asthma & Immunology. 2018; 120:34-41. doi.org/10.1016/j.anai.2017.09.055
43. Kim JE, Kim HS. Microbiome of the skin and gut in atopic dermatitis (ad): understanding the pathophysiology and finding novel management strategies. Journal of Clinical Medicine. 2019; 8:444-467. doi.org/10.3390/jcm8040444
44. Nakatsuji T, Chen TH, Narala S, Chun KA, Two AM, Yun T, et al. Antimicrobials from human skin commensal bacteria protect against Staphylococcus aureus and are deficient in atopic dermatitis. Science Translational Medicine. 2017; 9:eaah4680. doi.org/10.1126/scitranslmed.aah4680
45. Musso P, Chiappini E, Bernardini R. Human microbiome and allergic diseases in children: pathogenetic role and therapeutic options. Current Pediatric Reviews. 2019; 16:89-94. doi.org/10.2174/1573396315666191025110849
46. Pascal M, Perez-Gordo M, Caballero T, Escribese MM, Lopez Longo MN, Luengo O, et al. Microbiome and allergic diseases. Frontiers in Immunology. 2018; 9:1584. doi.org/10.3389/fimmu.2018.01584
47. Geoghegan JA, Irvine AD, Foster TJ. Staphylococcus aureus and atopic dermatitis: a complex and evolving relationship. Trends in Microbiology. 2018; 26:484-497. doi.org/10.1016/ j.tim.2017.11.008
48. Stalder JF, Fluhr JW, Foster T, Glatz M, Proksch E. The emerging role of skin microbiome in atopic dermatitis and its clinical implication. The Journal of Dermatological Treatment. 2019; 30:357-364. doi.org/10.1080/09546634.2018.1516030
49. Thomas L, Fernández-Peñas P. The microbiome and atopic eczema: more than skin deep. Australasian Journal of Dermatology. 2017; 58:18-24. doi.org/10.1111/ajd.12435
50. Wollina U. Microbiome in atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology. 2017; 10:51-65. doi.org/10.2147/CCID.S130013
51. Shi B, Leung D, Taylor PA, Li H. Methicillin-resistant staphylococcus aureus colonisation is associated with decreased skin commensal bacteria in atopic dermatitis. The Journal of Investigative Dermatology. 2018; 138:1668-1671. doi.org/10.1016/j.jid.2018.01.022
52. Wang Z, MacLeod DT, Di Nardo A. Commensal bacteria lipoteichoic acid increases skin mast cell antimicrobial activity against vaccinia viruses. The Journal of Immunology. 2012; 189:1551-1558. doi.org/10.4049/jimmunol.1200471
53. Blanchet-Réthoré S, Bourdès V, Mercenier A, Haddar CH, Verhoeven PO, Andres P. Effect of a lotion containing the heat-treated probiotic strain Lactobacillus johnsonii NCC 533 on Staphylococcus aureus colonisation in atopic dermatitis. Clinical, Cosmetic and Investigational Dermatology. 2017; 10:249-257. doi.org/10.2147/CCID.S135529
54. Nodake Y, Matsumoto S, Miura R, Honda H, Ishibashi G, Matsumoto S, et al. Pilot study on novel skin care method by augmentation with Staphylococcus epidermidis, an autologous skin microbe–A blinded randomised clinical trial. The Journal of Dermatological Science. 2015; 79:119-126. doi.org/10.1016/j.jdermsci.2015.05.001
55. Neroyev V, Saakian S, Miakoshina E, Iurovskaia N, Riabina M, Zaĭtseva O, Lysenko V. Differential diagnosis of early central choroidal melanoma and late stage age-related macula degeneration. Vestnik Oftalmologii. 2013;129(1):39-45
56. Krichevskaya G, Slepova O, Sahakyan S, Myakoshina E, Denisova Y. On the role of infections in the pathogenesis of retinoblastoma. Russian Ophthalmological Journal. 2013; 6(2):37-40.